Dianthus reports Q3 net loss $14.8M; positive Phase 1 data for DNTH103, cash $189.9M

Dianthus Therapeutics, Inc. /DE/

2023-Q3 EPS reported -$17.40 revenue$2,369,000

Net loss of $14.8M ($3.78 per share); R&D expenses $8.0M, G&A $8.7M including $4.0M severance.
Cash, equivalents, and investments $189.9M at Sept. 30, 2023; runway into Q2 2026.
Phase 1 data: ~60-day half-life, potent classical complement inhibition, no serious adverse events.
Plan to start Phase 2 trials: gMG in Q1 2024, followed by MMN (1H24) and CIDP (2H24).
Completed merger with Magenta Therapeutics and $72M private placement led by Fidelity and others.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Dianthus Therapeutics, Inc. /DE/ reported third quarter ending September 30, 2023 results: net income $14.8 million, EPS $3.78 net loss per share (basic and diluted).

Period: third quarter ending September 30, 2023
Net income: $14.8 million
EPS: $3.78 net loss per share (basic and diluted)
Result: reported results

Exact text from the filing

Net loss for the quarter ended September 30, 2023 was $14.8 million or $3.78 net loss per share (basic and diluted).

View on SEC.gov

41 earnings releases filed in the last 30 days. Browse all earnings releases →

Dianthus Therapeutics, Inc. /DE/ filing history →

Source: SEC EDGAR

accession 0000950170-23-062034

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.